Ardent Health Inc. (ARDT) Income Statement

The reported revenue of $1.6B in 2026Q2 is essentially flat sequentially and down 1.4% year-over-year, a sharp reversal from the 11.9% growth seen in 2025Q2. This deceleration may indicate softening patient volumes or payer mix shifts, though the maintained guidance suggests management sees this as temporary. Investors should monitor whether this is a one-off or the start of a sustained slowdown, especially given the company's geographic concentration in Texas, Oklahoma, and New Mexico.

The dramatic fluctuation in gross margin—from 83.6% to 6.0%—is likely due to changes in expense classification, as the company appears to shift clinical labor costs between COGS and operating expenses. This makes peer comparison difficult, but the operating margin of 2.7% in 2026Q2 is well below the 8.3% reported a year earlier, indicating real margin pressure. The high fixed-cost structure and sensitivity to labor inflation are evident, and the company's ability to pass on costs to payers will be critical.

The 69% drop in operating income from $137.3M in 2025Q2 to $43.2M in 2026Q2, despite a mere 1.4% revenue decline, highlights a severe negative operating leverage. This suggests that fixed costs, particularly labor, are not being absorbed by volume, and the company may be facing wage inflation or increased contract labor usage. The thin 2.7% operating margin leaves little room for error, and management's ability to control SG&A and clinical costs will be key to restoring profitability.

The company's cost structure is heavily weighted toward SG&A, which appears to include most clinical labor and supply costs, given the minimal COGS in some quarters. In 2025Q2, SG&A was $1.0B against revenue of $1.6B, a 62.5% ratio, and similar levels in 2024Q2. This indicates that labor costs are the primary driver of profitability, and any wage inflation or staffing shortages directly pressure margins. The recent EPS miss suggests that cost escalation is outpacing revenue growth, and management's expense discipline will be crucial.

The 2024Q4 quarter stands out as an outlier with operating margin of 21.0% and net margin of 7.1%, far above the typical 5% operating margin. This spike may have been driven by one-time items, such as supplemental reimbursements or favorable payer settlements, which are not sustainable. The subsequent quarters reverted to lower margins, indicating that the company's baseline profitability is much thinner. This volatility suggests that investors should not extrapolate from any single quarter and should focus on normalized earnings power.